Racura Oncology Ltd (asx:RAC) Share Price

Company Profile

Business description
Racura Oncology Ltdis a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Racura's primary asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that functions by binding to G4-DNA and RNA, resulting to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent researchs made by the company have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1. Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications.
Contact
1 Macquarie Place
Level 36
Gateway
SydneyNSW2000
AUS
T: +61 280513043
https://www.racuraoncology.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees

Recommended

The stocks of these high-quality companies with large market capitalizations look undervalued today.

Margaret Giles | 02 February 2026

Prices of these shares exceed our Fair Value Estimate by more than double.

Morningstar | 02 February 2026

Compounders tend to deliver steadier, more durable profit growth across full cycles, making them better suited for long-term investors.

Robert M. Almeida | 02 February 2026

Index	Last price	Change	% Change
All Ordinaries	9,058.00	53.00	-0.58%
CAC 40	8,126.53	55.17	0.68%
DAX 40	24,538.81	229.35	0.94%
Dow JONES (US)	48,892.47	179.09	-0.36%
FTSE 100	10,223.54	51.78	0.51%
HKSE	26,830.50	556.61	-2.03%
NASDAQ	23,461.82	223.30	-0.94%
Nikkei 225	53,422.01	99.16	0.19%
NZX 50 Index	13,399.08	24.10	-0.18%
S&P 500	6,939.03	29.98	-0.43%
S&P/ASX 200	8,766.70	54.40	-0.62%
SSE Composite Index	4,076.97	40.98	-1.00%